The biotech sector, as measured by the XBI ETF, fell 2.00% in the current session, mirroring a wider market downturn led by a sell-off in technology and AI-related stocks. There is no apparent, new negative catalyst specific to the biotechnology industry today. The decline is most likely attributable to broad market sentiment, where investors are reducing exposure to higher-risk growth sectors amidst geopolitical uncertainty and ahead of key economic data releases.